Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-02-27

FDA Approved: APRETUDE — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

FDA approved a supplemental application for APRETUDE (cabotegravir) by ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • APRETUDE (CABOTEGRAVIR)

Snippet

SUPPL AP for APRETUDE (CABOTEGRAVIR)